Our news News & Events

4Moving Biotech, a spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD) announces the equity investment of the Arthritis Foundation to support the clinical development of its disease-modifying osteoarthritis drug candidate. “We are very pleased with the commitment of the Foundation Arthritis. Patients have always been the core of our&hellip

4Moving Biotech, a biotechnology company and subsidiary of 4P-Pharma, focusing on the development of 4P004, a first-in-class disease modifying osteoarthritis drug (DMOAD) for a curative treatment of osteoarthritis, announces that it has enrolled its first patient for phase I of LASARE clinical trial study. “We are so excited to have the first patient enrolled in our first-in-human phase&hellip

4P-Pharma is present at BIO Europe 2022! ​Join us at the digital event. Roselina Lam, our Business Development and Licensing–in Manager, will attend the upcoming BIO Europe on October 24-26, 2022 in Leipzig, Germany! To learn more about us, our pipeline and discuss future partnership, please feel free to connect with us by e-mail or via the partnering platform.​ For further information, click here!

4P-Pharma is attending to BioJapan, as a part of french biotechnology company partner with Business France-Santé delegation, from October 12th to 14th in Yokohama, Japan. Meet our CEO, Revital Rattenbach in person during the event.   Keep in touch with Roselina Lam, our Business development and Licensing-in manager to be informed about our portfolio or to discuss&hellip

4P-Pharma is delighted to welcome Emmanuelle Lopez appointed as a Chief Financial Officer. She has substantial experience and background in both pharma and biotech companies. Emmanuelle Lopez is joining our company at its best time where we are taking an important turn in our growth with the start of our clinical trials. Together, we are&hellip

4P-Pharma is in « Innovations and Biotechnology » special dossier of Entreprendre magazine (issue 360, July/ August 2022). Here you can find our article about our innovative drug development approach, presented by Revital Rattenbach, founder and CEO of 4P-Pharma : click her